Mining the cancer genome uncovers therapeutic activity of EphA7 against lymphoma

References

• Oricchio E, Nanjangud G, Wolfe AL, Schatz JH, Mavrakis KJ, Jiang M, et al. The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell 2011; 147:554 - 564; PMID: 22036564; http://dx.doi.org/10.1016/j.cell.2011.09.035
   PubMed Web of Science ®Google Scholar
• Oricchio E, Wolfe AL, Schatz JH, Mavrakis KJ, Wendel HG. Mouse models of cancer as biological filters for complex genomic data. Dis Model Mech 2010; 3:701 - 704; PMID: 20876355; http://dx.doi.org/10.1242/dmm.006296
   PubMed Web of Science ®Google Scholar
• Bende RJ, Smit LA, van Noesel CJ. Molecular pathways in follicular lymphoma. Leukemia 2007; 21:18 - 29; PMID: 17039231; http://dx.doi.org/10.1038/sj.leu.2404426
   PubMed Web of Science ®Google Scholar
• Staudt LM, Wilson WH. Focus on lymphomas. Cancer Cell 2002; 2:363 - 366; PMID: 12450791; http://dx.doi.org/10.1016/S1535-6108(02)00178-2
   PubMed Web of Science ®Google Scholar
• Gaidano G, Hauptschein RS, Parsa NZ, Offit K, Rao PH, Lenoir G, et al. Deletions involving two distinct regions of 6q in B-cell non-Hodgkin lymphoma. Blood 1992; 80:1781 - 1787; PMID: 1356511
   PubMed Web of Science ®Google Scholar
• Offit K, Parsa NZ, Gaidano G, Filippa DA, Louie D, Pan D, et al. 6q deletions define distinct clinico-pathologic subsets of non-Hodgkin lymphoma. Blood 1993; 82:2157 - 2162; PMID: 8104536
   PubMed Web of Science ®Google Scholar
• Nanjangud G, Rao PH, Teruya-Feldstein J, Donnelly G, Qin J, Mehra S, et al. Molecular cytogenetic analysis of follicular lymphoma (FL) provides detailed characterization of chromosomal instability associated with the t(14;18)(q32;q21) positive and negative subsets and histologic progression. Cytogenet Genome Res 2007; 118:337 - 344; PMID: 18000388; http://dx.doi.org/10.1159/000108318
   PubMed Web of Science ®Google Scholar
• Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011; 476:298 - 303; PMID: 21796119; http://dx.doi.org/10.1038/nature10351
   PubMed Web of Science ®Google Scholar
• Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010; 42:181 - 185; PMID: 20081860; http://dx.doi.org/10.1038/ng.518
   PubMed Web of Science ®Google Scholar
• McCaffrey AP, Meuse L, Pham TT, Conklin DS, Hannon GJ, Kay MA. RNA interference in adult mice. Nature 2002; 418:38 - 39; PMID: 12097900; http://dx.doi.org/10.1038/418038a
   PubMed Web of Science ®Google Scholar
• Dickins RA, Hemann MT, Zilfou JT, Simpson DR, Ibarra I, Hannon GJ, et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet 2005; 37:1289 - 1295; PMID: 16200064
   PubMed Web of Science ®Google Scholar
• Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006; 125:1253 - 1267; PMID: 16814713; http://dx.doi.org/10.1016/j.cell.2006.05.030
   PubMed Web of Science ®Google Scholar
• Schlabach MR, Luo J, Solimini NL, Hu G, Xu Q, Li MZ, et al. Cancer proliferation gene discovery through functional genomics. Science 2008; 319:620 - 624; PMID: 18239126; http://dx.doi.org/10.1126/science.1149200
   PubMed Web of Science ®Google Scholar
• Silva JM, Marran K, Parker JS, Silva J, Golding M, Schlabach MR, et al. Profiling essential genes in human mammary cells by multiplex RNAi screening. Science 2008; 319:617 - 620; PMID: 18239125; http://dx.doi.org/10.1126/science.1149185
   PubMed Web of Science ®Google Scholar
• Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, Ma B, et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 2008; 135:852 - 864; PMID: 19012953; http://dx.doi.org/10.1016/j.cell.2008.09.061
   PubMed Web of Science ®Google Scholar
• Bric A, Miething C, Bialucha CU, Scuoppo C, Zender L, Krasnitz A, et al. Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell 2009; 16:324 - 335; PMID: 19800577; http://dx.doi.org/10.1016/j.ccr.2009.08.015
   PubMed Web of Science ®Google Scholar
• Egle A, Harris AW, Bath ML, O'Reilly L, Cory S. VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia. Blood 2004; 103:2276 - 2283; PMID: 14630790; http://dx.doi.org/10.1182/blood-2003-07-2469
   PubMed Web of Science ®Google Scholar
• Pasquale EB. Eph-ephrin bidirectional signaling in physiology and disease. Cell 2008; 133:38 - 52; PMID: 18394988; http://dx.doi.org/10.1016/j.cell.2008.03.011
   PubMed Web of Science ®Google Scholar
• Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 2010; 10:165 - 180; PMID: 20179713; http://dx.doi.org/10.1038/nrc2806
   PubMed Web of Science ®Google Scholar
• Depaepe V, Suarez-Gonzalez N, Dufour A, Passante L, Gorski JA, Jones KR, et al. Ephrin signalling controls brain size by regulating apoptosis of neural progenitors. Nature 2005; 435:1244 - 1250; PMID: 15902206; http://dx.doi.org/10.1038/nature03651
   PubMed Web of Science ®Google Scholar
• Nie D, Di Nardo A, Han JM, Baharanyi H, Kramvis I, Huynh T, et al. Tsc2-Rheb signaling regulates EphA-mediated axon guidance. Nat Neurosci 2010; 13:163 - 172; PMID: 20062052; http://dx.doi.org/10.1038/nn.2477
   PubMed Web of Science ®Google Scholar
• Sawamiphak S, Seidel S, Essmann CL, Wilkinson GA, Pitulescu ME, Acker T, et al. Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature 2010; 465:487 - 491; PMID: 20445540; http://dx.doi.org/10.1038/nature08995
   PubMed Web of Science ®Google Scholar
• Holmberg J, Clarke DL, Frisén J. Regulation of repulsion versus adhesion by different splice forms of an Eph receptor. Nature 2000; 408:203 - 206; PMID: 11089974; http://dx.doi.org/10.1038/35041577
   PubMed Web of Science ®Google Scholar
• Dawson DW, Hong JS, Shen RR, French SW, Troke JJ, Wu YZ, et al. Global DNA methylation profiling reveals silencing of a secreted form of Epha7 in mouse and human germinal center B-cell lymphomas. Oncogene 2007; 26:4243 - 4252; PMID: 17260020; http://dx.doi.org/10.1038/sj.onc.1210211
   PubMed Web of Science ®Google Scholar
• Kuang SQ, Bai H, Fang ZH, Lopez G, Yang H, Tong W, et al. Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia. Blood 2010; 115:2412 - 2419; PMID: 20061560; http://dx.doi.org/10.1182/blood-2009-05-222208
   PubMed Web of Science ®Google Scholar
• Wang J, Kataoka H, Suzuki M, Sato N, Nakamura R, Tao H, et al. Downregulation of EphA7 by hypermethylation in colorectal cancer. Oncogene 2005; 24:5637 - 5647; PMID: 16007213; http://dx.doi.org/10.1038/sj.onc.1208720
   PubMed Web of Science ®Google Scholar
• Guan M, Xu C, Zhang F, Ye C. Aberrant methylation of EphA7 in human prostate cancer and its relation to clinicopathologic features. Int J Cancer 2009; 124:88 - 94; PMID: 18821581; http://dx.doi.org/10.1002/ijc.23890
   PubMed Web of Science ®Google Scholar
• Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455:1069 - 1075; PMID: 18948947; http://dx.doi.org/10.1038/nature07423
   PubMed Web of Science ®Google Scholar
• Lisabeth EM, Fernandez C, Pasquale EB. Cancer Somatic Mutations Disrupt Functions of the EphA3 Receptor Tyrosine Kinase Through Multiple Mechanisms. Biochemistry 2012; PMID: 22242939; http://dx.doi.org/10.1021/bi2014079
   PubMed Web of Science ®Google Scholar
• Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 2001; 61:2301 - 2306; PMID: 11280802
   PubMed Web of Science ®Google Scholar
• Lu C, Shahzad MM, Wang H, Landen CN, Kim SW, Allen J, et al. EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther 2008; 7:1098 - 1103; PMID: 18443431; http://dx.doi.org/10.4161/cbt.7.7.6168
   PubMed Web of Science ®Google Scholar
• Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445:656 - 660; PMID: 17251933; http://dx.doi.org/10.1038/nature05529
   PubMed Web of Science ®Google Scholar
• Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007; 445:661 - 665; PMID: 17251932; http://dx.doi.org/10.1038/nature05541
   PubMed Web of Science ®Google Scholar
• Weinstein IB. Cancer. Addiction to oncogenes—the Achilles heal of cancer. Science 2002; 297:63 - 64; PMID: 12098689; http://dx.doi.org/10.1126/science.1073096
   PubMed Web of Science ®Google Scholar
• Sharma SV, Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 2007; 21:3214 - 3231; PMID: 18079171; http://dx.doi.org/10.1101/gad.1609907
   PubMed Web of Science ®Google Scholar
• Kato M, Sanada M, Kato I, Sato Y, Takita J, Takeuchi K, et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009; 459:712 - 716; PMID: 19412163; http://dx.doi.org/10.1038/nature07969
   PubMed Web of Science ®Google Scholar
• Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, et al. Mutations of multiple genes cause deregulation of NFkappaB in diffuse large B-cell lymphoma. Nature 2009; 459:717 - 721; PMID: 19412164; http://dx.doi.org/10.1038/nature07968
   PubMed Web of Science ®Google Scholar
• Mandelbaum J, Bhagat G, Tang H, Mo T, Brahmachary M, Shen Q, et al. BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell 2010; 18:568 - 579; PMID: 21156281; http://dx.doi.org/10.1016/j.ccr.2010.10.030
   PubMed Web of Science ®Google Scholar
• De S, Michor F. DNA replication timing and long-range DNA interactions predict mutational landscapes of cancer genomes. Nat Biotechnol 2011; 29:1103 - 1108; PMID: 22101487; http://dx.doi.org/10.1038/nbt.2030
   PubMed Web of Science ®Google Scholar